Halozyme Therapeutics Inc (HALO.OQ)

HALO.OQ on NASDAQ Stock Exchange Global Select Market

9.20USD
1:21pm EDT
Price Change (% chg)

$-0.09 (-0.97%)
Prev Close
$9.29
Open
$9.33
Day's High
$9.38
Day's Low
$9.12
Volume
248,018
Avg. Vol
578,711
52-wk High
$18.15
52-wk Low
$6.51

HALO.OQ

Chart for HALO.OQ

About

Halozyme Therapeutics, Inc. is a biopharmaceutical company. The Company’s research focuses primarily on human enzymes that alter the extracellular matrix. The Company’s pipeline consists of multiple clinical stage products in diabetes, oncology and dermatology. The product candidates in its pipeline are based on rHuPH20, a... (more)

Overall

Beta: 1.59
Market Cap (Mil.): $1,156.45
Shares Outstanding (Mil.): 124.48
Dividend: --
Yield (%): --

Financials

  HALO.OQ Industry Sector
P/E (TTM): -- 106.71 36.40
EPS (TTM): -0.79 -- --
ROI: -70.22 0.13 18.27
ROE: -184.37 -0.64 19.15
Search Stocks

Halozyme shares jump after FDA lifts hold on trial

- Shares of Halozyme Therapeutics Inc jumped about 11 percent a day after the U.S. Food and Drug Administration lifted a hold on a trial testing an advanced version of the company's flagship drug delivery technology.

05 Jun 2014

Halozyme shares jump after FDA lifts hold on trial

June 5 - Shares of Halozyme Therapeutics Inc jumped about 11 percent a day after the U.S. Food and Drug Administration lifted a hold on a trial testing an advanced version of the company's flagship drug delivery technology.

05 Jun 2014

FDA halts Halozyme's pancreatic cancer study

- Halozyme Therapeutics Inc said the U.S. Food and Drug Administration ordered a halt on a study of its drug delivery system in pancreatic cancer patients, barely a week after the company voluntarily stopped the trial.

09 Apr 2014

FDA halts Halozyme's pancreatic cancer study

April 9 - Halozyme Therapeutics Inc said the U.S. Food and Drug Administration ordered a halt on a study of its drug delivery system in pancreatic cancer patients, barely a week after the company voluntarily stopped the trial.

09 Apr 2014

Halozyme halts trial of drug delivery system, shares slump

- Halozyme Therapeutics Inc halted a mid-stage trial testing an advanced version of its flagship drug delivery technology in patients with pancreatic cancer, sending its shares tumbling 32 percent.

04 Apr 2014

UPDATE 2-Halozyme halts trial of drug delivery system, shares slump

April 4 - Halozyme Therapeutics Inc halted a mid-stage trial testing an advanced version of its flagship drug delivery technology in patients with pancreatic cancer, sending its shares tumbling 32 percent.

04 Apr 2014

MARKET PULSE-Deckers, Vaalco, NII Holdings, Nimble Storage, Halozyme

U.S. stock index futures dipped on Friday, with investors reluctant to make big bets after the S&P 500 closed at a record and ahead of closely watched data on economic growth. Dow Jones industrial average futures were down 0.04 percent at 16,266, S&P 500 futures were down 0.11 percent at 1,851.9 and Nasdaq 100 futures were down 0.05 percent at 3,699.5.

28 Feb 2014

Competitors

  Price Change
Novo Nordisk A/S (NOVOb.CO) kr.251.50 -4.70
Sanofi SA (SASY.PA) €77.32 +0.39
Eli Lilly and Co (LLY.N) $64.49 +0.24
Biodel Inc (BIOD.OQ) $1.95 +0.03
MannKind Corporation (MNKD.OQ) $9.38 -0.18

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Sadif Analytics (Premium)
$10.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks